Osocimab, formerly known as BAY 1213790, represents a novel monoclonal immunoglobulin currently experiencing clinical development for the treatment of various hematologic cancers. This compound specifically targets https://deweyaowe935570.blog-gold.com/58647379/osocimab-a-deep-analysis-into-bay-1213790-and-its-outlook